Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.98
CELG's Cash to Debt is ranked lower than
78% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 60.34 vs. CELG: 0.98 )
Ranked among companies with meaningful Cash to Debt only.
CELG' s 10-Year Cash to Debt Range
Min: 0.03  Med: 1.88 Max: No Debt
Current: 0.98
Equity to Asset 0.36
CELG's Equity to Asset is ranked lower than
78% of the 594 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. CELG: 0.36 )
Ranked among companies with meaningful Equity to Asset only.
CELG' s 10-Year Equity to Asset Range
Min: -0.68  Med: 0.60 Max: 0.92
Current: 0.36
-0.68
0.92
Interest Coverage 14.30
CELG's Interest Coverage is ranked lower than
89% of the 375 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CELG: 14.30 )
Ranked among companies with meaningful Interest Coverage only.
CELG' s 10-Year Interest Coverage Range
Min: 4.47  Med: 23.69 Max: 428.04
Current: 14.3
4.47
428.04
F-Score: 7
Z-Score: 7.50
M-Score: -2.57
WACC vs ROIC
16.78%
38.15%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 31.72
CELG's Operating margin (%) is ranked higher than
94% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -69.59 vs. CELG: 31.72 )
Ranked among companies with meaningful Operating margin (%) only.
CELG' s 10-Year Operating margin (%) Range
Min: -2309.09  Med: 5.17 Max: 32.84
Current: 31.72
-2309.09
32.84
Net-margin (%) 26.08
CELG's Net-margin (%) is ranked higher than
92% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -66.45 vs. CELG: 26.08 )
Ranked among companies with meaningful Net-margin (%) only.
CELG' s 10-Year Net-margin (%) Range
Min: -2309.09  Med: 8.57 Max: 28.88
Current: 26.08
-2309.09
28.88
ROE (%) 36.34
CELG's ROE (%) is ranked higher than
96% of the 761 Companies
in the Global Biotechnology industry.

( Industry Median: -29.50 vs. CELG: 36.34 )
Ranked among companies with meaningful ROE (%) only.
CELG' s 10-Year ROE (%) Range
Min: -425.42  Med: 8.93 Max: 33.02
Current: 36.34
-425.42
33.02
ROA (%) 12.99
CELG's ROA (%) is ranked higher than
93% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: -25.57 vs. CELG: 12.99 )
Ranked among companies with meaningful ROA (%) only.
CELG' s 10-Year ROA (%) Range
Min: -166.78  Med: 4.51 Max: 15.8
Current: 12.99
-166.78
15.8
ROC (Joel Greenblatt) (%) 208.68
CELG's ROC (Joel Greenblatt) (%) is ranked higher than
96% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: -333.14 vs. CELG: 208.68 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CELG' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1378.72  Med: 99.64 Max: 212.3
Current: 208.68
-1378.72
212.3
Revenue Growth (3Y)(%) 20.60
CELG's Revenue Growth (3Y)(%) is ranked higher than
78% of the 404 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. CELG: 20.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
CELG' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: 35.70 Max: 166.8
Current: 20.6
0
166.8
EBITDA Growth (3Y)(%) 20.40
CELG's EBITDA Growth (3Y)(%) is ranked higher than
77% of the 427 Companies
in the Global Biotechnology industry.

( Industry Median: -3.90 vs. CELG: 20.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CELG' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0  Med: 21.90 Max: 75.6
Current: 20.4
0
75.6
EPS Growth (3Y)(%) 19.00
CELG's EPS Growth (3Y)(%) is ranked higher than
77% of the 413 Companies
in the Global Biotechnology industry.

( Industry Median: -7.70 vs. CELG: 19.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CELG' s 10-Year EPS Growth (3Y)(%) Range
Min: -63.2  Med: 23.55 Max: 118.1
Current: 19
-63.2
118.1
» CELG's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

CELG Guru Trades in Q3 2014

John Hussman 25,000 sh (New)
Louis Moore Bacon 55,000 sh (New)
Stanley Druckenmiller 560,600 sh (+103.12%)
Ken Fisher 232,137 sh (+77.12%)
RS Investment Management 86,904 sh (+15.71%)
Mario Gabelli 25,760 sh (+11.42%)
Ronald Muhlenkamp 146,940 sh (+1.94%)
Pioneer Investments 3,080,374 sh (unchged)
George Soros Sold Out
Joel Greenblatt Sold Out
Jeremy Grantham Sold Out
Steven Cohen Sold Out
Jim Simons 30,400 sh (-93.87%)
» More
Q4 2014

CELG Guru Trades in Q4 2014

Paul Tudor Jones 3,776 sh (New)
Joel Greenblatt 10,259 sh (New)
Steven Cohen 110,400 sh (New)
Pioneer Investments 3,376,570 sh (+9.62%)
Louis Moore Bacon Sold Out
John Hussman Sold Out
Jim Simons Sold Out
Ken Fisher 227,331 sh (-2.07%)
Mario Gabelli 24,960 sh (-3.11%)
RS Investment Management 76,482 sh (-11.99%)
Stanley Druckenmiller 434,100 sh (-22.57%)
Ronald Muhlenkamp 86,240 sh (-41.31%)
» More
Q1 2015

CELG Guru Trades in Q1 2015

Lee Ainslie 2,230 sh (New)
Jim Simons 425,600 sh (New)
Ray Dalio 24,296 sh (New)
Murray Stahl 5,000 sh (New)
Bill Frels 1,776 sh (New)
Joel Greenblatt 17,987 sh (+75.33%)
RS Investment Management 97,369 sh (+27.31%)
Pioneer Investments 3,475,247 sh (+2.92%)
Ken Fisher 229,918 sh (+1.14%)
Steven Cohen 1,000,200 sh (unchged)
Steven Cohen Sold Out
Mario Gabelli 24,940 sh (-0.08%)
Ronald Muhlenkamp 85,540 sh (-0.81%)
Paul Tudor Jones 3,180 sh (-15.78%)
Stanley Druckenmiller 195,975 sh (-54.85%)
» More
Q2 2015

CELG Guru Trades in Q2 2015

Ken Fisher 224,399 sh (-2.40%)
» More
» Details

Insider Trades

Latest Guru Trades with CELG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 49.92
CELG's P/E(ttm) is ranked lower than
53% of the 215 Companies
in the Global Biotechnology industry.

( Industry Median: 41.60 vs. CELG: 49.92 )
Ranked among companies with meaningful P/E(ttm) only.
CELG' s 10-Year P/E(ttm) Range
Min: 17.91  Med: 49.05 Max: 618.59
Current: 49.92
17.91
618.59
Forward P/E 21.65
CELG's Forward P/E is ranked higher than
56% of the 162 Companies
in the Global Biotechnology industry.

( Industry Median: 24.04 vs. CELG: 21.65 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 50.10
CELG's PE(NRI) is ranked lower than
54% of the 213 Companies
in the Global Biotechnology industry.

( Industry Median: 39.20 vs. CELG: 50.10 )
Ranked among companies with meaningful PE(NRI) only.
CELG' s 10-Year PE(NRI) Range
Min: 17.81  Med: 48.81 Max: 482.5
Current: 50.1
17.81
482.5
P/B 17.19
CELG's P/B is ranked lower than
88% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. CELG: 17.19 )
Ranked among companies with meaningful P/B only.
CELG' s 10-Year P/B Range
Min: 4.02  Med: 9.20 Max: 23.45
Current: 17.19
4.02
23.45
P/S 12.99
CELG's P/S is ranked lower than
54% of the 591 Companies
in the Global Biotechnology industry.

( Industry Median: 11.60 vs. CELG: 12.99 )
Ranked among companies with meaningful P/S only.
CELG' s 10-Year P/S Range
Min: 5.37  Med: 10.85 Max: 28.35
Current: 12.99
5.37
28.35
PFCF 41.14
CELG's PFCF is ranked higher than
55% of the 144 Companies
in the Global Biotechnology industry.

( Industry Median: 45.01 vs. CELG: 41.14 )
Ranked among companies with meaningful PFCF only.
CELG' s 10-Year PFCF Range
Min: 14.96  Med: 36.67 Max: 2925.5
Current: 41.14
14.96
2925.5
POCF 38.16
CELG's POCF is ranked higher than
50% of the 203 Companies
in the Global Biotechnology industry.

( Industry Median: 35.83 vs. CELG: 38.16 )
Ranked among companies with meaningful POCF only.
CELG' s 10-Year POCF Range
Min: 13.82  Med: 33.79 Max: 937.83
Current: 38.16
13.82
937.83
EV-to-EBIT 36.85
CELG's EV-to-EBIT is ranked lower than
54% of the 224 Companies
in the Global Biotechnology industry.

( Industry Median: 32.56 vs. CELG: 36.85 )
Ranked among companies with meaningful EV-to-EBIT only.
CELG' s 10-Year EV-to-EBIT Range
Min: -26.2  Med: 36.35 Max: 191.9
Current: 36.85
-26.2
191.9
PEG 2.17
CELG's PEG is ranked higher than
68% of the 73 Companies
in the Global Biotechnology industry.

( Industry Median: 2.63 vs. CELG: 2.17 )
Ranked among companies with meaningful PEG only.
CELG' s 10-Year PEG Range
Min: 1.38  Med: 1.93 Max: 2.92
Current: 2.17
1.38
2.92
Shiller P/E 77.25
CELG's Shiller P/E is ranked lower than
69% of the 109 Companies
in the Global Biotechnology industry.

( Industry Median: 49.43 vs. CELG: 77.25 )
Ranked among companies with meaningful Shiller P/E only.
CELG' s 10-Year Shiller P/E Range
Min: 56.57  Med: 139.79 Max: 2211
Current: 77.25
56.57
2211
Current Ratio 3.34
CELG's Current Ratio is ranked higher than
52% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: 4.37 vs. CELG: 3.34 )
Ranked among companies with meaningful Current Ratio only.
CELG' s 10-Year Current Ratio Range
Min: 1.35  Med: 6.66 Max: 44.53
Current: 3.34
1.35
44.53
Quick Ratio 3.20
CELG's Quick Ratio is ranked higher than
52% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. CELG: 3.20 )
Ranked among companies with meaningful Quick Ratio only.
CELG' s 10-Year Quick Ratio Range
Min: 1.13  Med: 6.56 Max: 44.15
Current: 3.2
1.13
44.15
Days Inventory 346.57
CELG's Days Inventory is ranked lower than
88% of the 399 Companies
in the Global Biotechnology industry.

( Industry Median: 118.21 vs. CELG: 346.57 )
Ranked among companies with meaningful Days Inventory only.
CELG' s 10-Year Days Inventory Range
Min: 49.98  Med: 122.84 Max: 584
Current: 346.57
49.98
584
Days Sales Outstanding 55.16
CELG's Days Sales Outstanding is ranked higher than
57% of the 558 Companies
in the Global Biotechnology industry.

( Industry Median: 60.65 vs. CELG: 55.16 )
Ranked among companies with meaningful Days Sales Outstanding only.
CELG' s 10-Year Days Sales Outstanding Range
Min: 42.33  Med: 57.52 Max: 464.55
Current: 55.16
42.33
464.55

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 574.52
CELG's Price/Tangible Book is ranked lower than
99% of the 687 Companies
in the Global Biotechnology industry.

( Industry Median: 5.90 vs. CELG: 574.52 )
Ranked among companies with meaningful Price/Tangible Book only.
CELG' s 10-Year Price/Tangible Book Range
Min: 4.05  Med: 11.90 Max: 338.97
Current: 574.52
4.05
338.97
Earnings Yield (Greenblatt) (%) 2.72
CELG's Earnings Yield (Greenblatt) (%) is ranked higher than
86% of the 813 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. CELG: 2.72 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CELG' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0.5  Med: 2.60 Max: 6.6
Current: 2.72
0.5
6.6
Forward Rate of Return (Yacktman) (%) 23.59
CELG's Forward Rate of Return (Yacktman) (%) is ranked higher than
69% of the 88 Companies
in the Global Biotechnology industry.

( Industry Median: 14.22 vs. CELG: 23.59 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
CELG' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: -0.1  Med: 1.10 Max: 34.8
Current: 23.59
-0.1
34.8

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CMXHY » details
Traded in other countries:CELG.Mexico, CG3.Germany, CELG.Switzerland, 0QYA.UK,
Celgene Corp is incorporated in Delaware. The Company is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of new therapies designed to treat cancer and immune-inflammatory related diseases. The Company is engaged in new research and development designed to bring new therapies to market and we are involved in research in several scientific areas that may deliver proprietary next-generation therapies, targeting areas including intracellular signaling pathways, protein homeostasis and epigenetics in cancer and immune cells, immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies. The Company' commercial stage products include REVLIMID(r), VIDAZA(r), ABRAXANE(r), POMALYST(r)/IMNOVID(r), THALOMID(r) (inclusive of Thalidomide CelgeneTM), ISTODAX(r) and azacitidine for injection (generic version of VIDAZA(r)). The Company faces competition from Amgen, AstraZeneca, Bristol-Myers-Squibb, Eisai, Gilead, Johnson & Johnson, Novartis, Pharmacyclics, Roche/Genentech, Sanofi and Takeda, AbbVie, Amgen, Biogen Idec, Eisai, Johnson & Johnson, Merck, Pfizer and UCB S.A. Regulation by governmental authorities in the United States and other countries is a significant factor in the manufacture and marketing of pharmaceuticals and in its ongoing research and development activities.
» More Articles for CELG

Headlines

Articles On GuruFocus.com
Stocks Jul 30 2015 
scottrade Jul 24 2015 
scottrade Jul 24 2015 
scottrade Jul 24 2015 
scottrade Jul 24 2015 
My Top 3 Pharma Stock Picks Jun 09 2015 
10 Reasons Why Growth Stocks Can Be Appropriate for Retired Investors Jun 04 2015 
Big Pharma Companies Are Betting On Regenerative Medicine - Should You? May 26 2015 
jee's porfolio May 23 2015 
Celgene’s Earnings Shine While Revenue Misses By An Inch In The First Quarter May 06 2015 

More From Other Websites
Celgene is pushed into paying a high price for Receptos Jul 30 2015
Large-Cap Healthcare Stocks Outperform Small Caps Jul 30 2015
Celgene Corp. Earnings Analysis: By the Numbers Jul 30 2015
Celgene says patent-fighting hedge fund manager wants to short its shares Jul 29 2015
Drugmakers Strike Back: Kyle Bass Blasted Over Patent Challenges Jul 29 2015
Q2 Earnings Season Halftime Report Jul 29 2015
Four Reasons Gilead Can Head Higher Jul 29 2015
Bristol-Myers Squibb Co. Earnings Analysis: By the Numbers Jul 29 2015
Under the radar names you're missing Jul 28 2015
NantKwest Surges As Biggest Biotech Market Cap IPO Jul 28 2015
Wait, Will Allergan Really Buy Biogen or Amgen? Jul 28 2015
Celgene Corporation Commences Tender Offer for Receptos, Inc. Jul 28 2015
Celgene Corporation Commences Tender Offer for Receptos, Inc. Jul 28 2015
CELGENE CORP /DE/ Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jul 28 2015
Gilead Earnings Preview and The Moment of Truth Jul 27 2015
Morgan Stanley Raises Price Target On Celgene, Still Highlights Several Risks Jul 27 2015
Biogen: Buy the Stock Get the Pipeline for Free Jul 27 2015
Cramer's Stop Trading: Biogen & GrubHub Jul 27 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK